The level of Tim-3⁺CD8⁺ T cells can serve as a potential marker for evaluating the severity of acute graft-versus-host disease after haplo-PBSCT

Early and accurate diagnosis of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation is crucial for the prognosis of patients. This study identified a potential biomarker for the severity of aGVHD after human leukocyte antigen (HLA)-haploidentical peripheral blood hematopoietic stem cell transplantation (haplo-PBSCT). We included 20 healthy subjects and 57 patients who underwent haplo-PBSCT. Of these patients, 22 developed aGVHD after haplo-PBSCT. The results showed that patients with aGVHD had significantly increased levels of Tim-3⁺/Perforin⁺/Granzyme B⁺CD8⁺ T cells, but significantly decreased Galectin-9. The differences in Galectin-9 and Tim-3⁺/Granzyme B⁺CD8⁺ T cells between grade I-II aGVHD and III-IV aGVHD were also significant. In vitro, the apoptosis of CD8⁺ T cells from aGVHD patients was significantly increased after Tim-3/Galectin-9 pathway activation, which decreased Granzyme B secretion. As revealed by univariate analysis, the level of Tim-3⁺CD8⁺ T cells was a risk factor for severe aGVHD. ROC analysis demonstrated that high levels of Tim-3⁺CD8⁺ T cells had a significant diagnostic value for severe aGVHD, with an area under the curve of 0.854 and cut-off value of 14.155%. In conclusion, the binding of Tim-3 with exogenous Galectin-9 can promote apoptosis of CD8⁺ T cells and affect the secretion of Granzyme B. Tim-3⁺CD8⁺ T cells have the potential to serve as immunological markers for assessing the severity of aGVHD after haplo-PBSCT and identifying patients at a higher risk for severe aGVHD.

haplo-PBSCT; Acute graft-versus-host disease; Tim-3; Galectin-9; Granzyme B